Basic facts about the French trial

By :

New Ebola Vaccine for Exposure Risk

The trial recruited 128 healthy volunteers aged 18–55, who were paid €1,900 (US$2,060) each. Ninety people received different doses of the drug, and the remainder a placebo. The trial had tested escalating single doses of the drug without observing any serious adverse side effects. The six participants who fell ill were the first to receive repeat higher doses over the course of several days. The first participant to fall ill experienced adverse symptoms on 10 January and died on 17 January. Biotrial halted the trial on 11 January; the other five affected people were hospitalized in the days that followed. One of these patients has since been discharged, and the condition of the other four is judged to be serious but stable. Authorities are contacting the 84 other people who received the drug at lower doses to arrange medical check-ups; none of the 18 given neurological check-ups over the weekend showed any of the symptoms seen in the hospitalized people. #health #clinicaltrial #braindead #biotrial #featured #frenchtrial #healthcare
Rate UsDon’t love itNot greatGoodGreatLove itRate Us
Your opinion
arrow&v
arrow&v

PHAF Team

Basic facts about the French trial

Event Management Team

An interview on Postmarket Drug Safety: The View from FDA

PHAF Team

French clinical trial : 1 dead , 5 hospitalized

PHAF DIC Team

FAQs on liver transplant answered by an expert

Event Management Team

Patient Need Both an Opioid and Benzodiazepine? : Expert Commentary

© 2019 PHAF  || All rights reserved

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon

Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.